Effects of treatment with antimicrobial agents on the human colonic microflora by Rafii, Fatemeh et al.
© 2008 Raﬁ  i et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2008:4(6) 1343–1357 1343
REVIEW
Effects of treatment with antimicrobial agents
on the human colonic microﬂ  ora
Fatemeh Rafii
John B Sutherland
Carl E Cerniglia
Division of Microbiology, National 
Center for Toxicological Research, 
FDA, Jefferson, AR, USA
Correspondence: Fatemeh Raﬁ  i
Division of Microbiology, National Center 
for Toxicological Research, FDA, Jefferson, 
AR 71602, USA
Tel +1 870 543 7342
Fax +1 870 543 7307
Email fatemeh.raﬁ  i@fda.hhs.gov
Abstract: Antimicrobial agents are the most valuable means available for treating bacterial 
infections. However, the administration of therapeutic doses of antimicrobial agents to patients 
is a leading cause of disturbance of the normal gastrointestinal microﬂ  ora. This disturbance 
results in diminishing the natural defense mechanisms provided by the colonic microbial eco-
system, making the host vulnerable to infection by commensal microorganisms or nosocomial 
pathogens. In this minireview, the impacts of antimicrobials, individually and in combinations, 
on the human colonic microﬂ  ora are discussed.
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Introduction
The human colonic microﬂ  ora ecosystem, its metabolic functions, and its colonization 
resistance are vital for the well-being of the host, production of vital metabolites, and 
prevention of infection (Edlund and Nord 1999b; Sullivan et al 2001a, 2001b). Various 
enzymes in the microbial ecosystem are implicated in deconjugation, reduction, and 
other biochemical activities, which result in altered bioavailability, activation, or detoxi-
ﬁ  cation of different molecules, including those drug metabolites released by the liver 
via bile ducts (Rowland 1995). In vitro models have shown that change in population 
composition of the human intestinal microﬂ  ora is concurrent with reduced colonization 
resistance (Wagner et al 2008). Furthermore, the microbial community may have 
an unknown inﬂ  uence on the immune system (van der Waaij and Nord 2000). The 
colonic microﬂ  ora appears to stimulate the host immune system to respond rapidly to 
pathogen challenges (Berg 1996). Although the cells of the intestinal tract coexist with 
the normal commensal microﬂ  ora, they recognize and clear invading pathogens before 
returning to homeostasis with the commensal bacteria. The roles and inﬂ  uences of 
different commensal bacteria vary. Host responses to the effects of commensal bacteria 
are genetically determined (Prantera et al 1997). In patients with inﬂ  ammatory bowel 
syndrome, the mucosal immune system shows an abnormal reaction to commensal 
bacteria in genetically susceptible individuals. The use of therapeutic agents to affect 
the bacterial population may result in microbial imbalances that affect health and cause 
disease. Based on clinical and epidemiological studies, it has been hypothesized that 
both the therapeutic use of antibiotics and the typical diets in industrialized countries 
may disrupt normal microbiota-mediated mechanisms of immunological tolerance in 
the mucosa, which also may result in an increase in allergic airway disease (Noverr 
and Huffnagle 2005). In the following sections, other effects of the clinical usage of 
antimicrobial agents on intestinal microﬂ  ora will be discussed.
Disturbance of the ecosystem
Although the colonic ecosystem is generally stable, it can be disturbed by the administration 
of antimicrobial agents for treatment or prophylaxis (Peck et al 1984). The colonic Therapeutics and Clinical Risk Management 2008:4(6) 1344
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bacteria are exposed to antimicrobial agents whether they are 
administered orally or through injection via the circulation 
(Edlund and Nord 1999b). This exposure may occur through 
incomplete absorption of antimicrobial agents administered 
orally, through exposure to antimicrobial agents in secretions 
by the salivary glands or intestinal mucosa or in bile from the 
liver (Nord et al 1984a, 1984b; Arvidsson et al 1988).
The extent of changes that occur in the intestinal micro-
ﬂ  ora community as the result of administration of antimi-
crobial agents depends on the antibacterial spectrum and 
its concentration in the luminal content (Nord et al 1984a, 
1984b). Antibiotics given orally that are absorbed in the 
upper part of the small intestine differ in their effects from 
those that are poorly absorbed. Parenteral antimicrobial 
agents, whether secreted in the bile or from mucosa, also 
affect susceptible bacterial populations (Nord and Edlund 
1990; Edlund and Nord 1999b). Exposure of the colonic 
ecosystem to antimicrobial agents may result in a shift in 
population of different components as the result of suppres-
sion or elimination of some microorganisms, overgrowth by 
microorganisms not susceptible to these agents, and estab-
lishment of antimicrobial-resistant members that normally 
are excluded (Nord 1993).
Effect of commensal 
microorganisms on colonization
Several factors contribute to the prevention of colonization by 
non-commensal microorganisms, among which are competi-
tion for nutrients, competition for attachment, and production 
of volatile fatty acids (Nord et al 1984b). Volatile fatty acids 
produced by anaerobic bacteria are toxic to some other spe-
cies, especially enterobacteria. Production of bacteriocins 
by enterobacteria, streptococci, and anaerobic bacteria also 
limits bacterial overgrowth.
Development of antimicrobial-
resistant bacteria
Another consequence of exposure to antibiotics that may have 
lasting effects is the emergence of antimicrobial-resistant 
bacteria that may cause problems in the long run (Nord and 
Edlund 1990). These organisms may be transmitted to dif-
ferent sites within the host, where they may cause infection, 
and to other hosts (Nord et al 1984b; Edlund and Nord 2000). 
An example is urinary tract infection caused by antimicrobial-
resistant Escherichia coli (Winberg et al 1993; Edlund and 
Nord 2000).
A multicenter susceptibility survey (Aldridge et al 
2001) has shown changes in the patterns of resistance 
among anaerobic bacteria to different antibiotics. Antibiotic 
resistance in anaerobic bacteria now is known for β-lactams, 
clindamycin, macrolides, tetracyclines, ﬂ  uoroquinolones, 
and nitroimidazole (Nord 2008). Methicillin-resistant 
Staphylococcus aureus (MRSA) strains have been isolated 
from children in an outpatient clinic who had microbial 
imbalances of the large intestine resulting from antibiotic 
use (Nikolaeva et al 2001).
Induction of enzymes in the colonic bacteria that make 
antimicrobial agents ineffective is another side effect of 
antimicrobial agents (Finegold 1986). Administration of 
β-lactams has resulted in increased levels of β-lactamases in 
the normal intestinal microﬂ  ora (Edlund et al 1994). Induc-
tion of β-lactamases in some aerobic and anaerobic bacteria 
by cefoxitin has been reported. However, since feces appear 
to inhibit the induction of β-lactamases, Stark and colleagues 
(1995) attribute increases in β-lactamases to the selection 
of “stably derepressed mutants” rather than to β-lactamase 
induction.
Fungal infections
Another problem that may arise as the result of antibiotic 
treatment is fungal acquisition (Louie et al 1985). Fungal 
overgrowth has been observed, speciﬁ  cally after treatment 
with antibiotics that reduce the population of anaerobic 
bacteria, in experimental animals, healthy individuals, and 
neutropenic patients (Kennedy and Voltz 1985; Louie et al 
1985; Pletz et al 2004). Louie and colleagues (1985) conclude, 
“Preservation of the anaerobic ﬂ  ora appears critical in the 
prevention of fungal acquisition in neutropenic patients.” 
Fungal infections may cause serious problems in immuno-
compromised patients, producing disseminated infections 
in various sites that could result in severe complications 
(Gauthier and Klein 2008).
Kennedy and colleagues (1987) used Candida albicans 
to challenge antibiotic-treated and untreated mice and found 
an association of the fungus with the intestinal epithelia of 
antibiotic-treated mice but not with those of the control 
mice that had indigenous bacterial ﬂ  ora. In the treated mice, 
some of the fungal cells penetrated deep into the mucosa of 
the intestinal tract, but most of them were associated with 
the cecal mucosa.
Effects on bacterial pathogenicity
Antimicrobial agents, in addition to limiting the effective-
ness of the colonization barrier by disturbing the normal 
intestinal microbiota, may also affect the pathogenicity 
of certain bacteria. Fluoroquinolones have been shown to Therapeutics and Clinical Risk Management 2008:4(6) 1345
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induce bacteriophages and enhance Shiga toxin production 
in E. coli O157:H7, which may increase the virulence of this 
strain (Zhang et al 2000). In our laboratory, one out of ﬁ  ve 
gatiﬂ  oxacin-resistant Clostridium perfringens strains also had 
enhanced production of phospholipase C and perfringolysin O 
(Raﬁ  i et al 2008). Subinhibitory concentrations of ampicillin 
and clindamycin may directly affect adherence of Clostridium 
difﬁ  cile by increasing the expression of genes necessary for 
colonization (Deneve et al 2008). In an in vitro animal study, 
it was shown that subcutaneous administration of antibiotics 
that disrupt anaerobic ﬂ  ora facilitated the growth and toxin 
production of C. difﬁ  cile in mouse cecal contents. Antibiotics 
that did not have major effects on anaerobic populations did 
not affect growth or toxin production (Pultz and Donskey 
2005). These ﬁ  ndings justify the concerns of government 
regulatory agencies, the World Health Organization, and 
health care professionals about the use of antimicrobial agents 
in farm animals (Cerniglia and Kotarski 1999).
Other side effects
The use of antimicrobial agents usually is accompanied 
by gastrointestinal upsets, especially antibiotic-associated 
diarrhea, which frequently is resolved shortly after dis-
continuance of the antimicrobial agent and the return 
of balance to the ecosystem (Nord and Edlund 1990). It 
occurs in 15%–25% of patients treated with antibiotics and 
its incidence differs with various antibiotics. It is caused 
by mild to severe disturbance of gut microﬂ  ora; the mild 
cases may result from disturbances in carbohydrate or bile 
acid metabolism. Proliferation of pathogens as the result 
of this disturbance may cause severe cases of antibiotic-
associated diarrhea (Schröder et al 2006).
In an immunocompromised host, or those weakened by 
surgery or advanced age, severe infections by opportunistic 
pathogens can occur. Potential pathogens, like C. difﬁ  cile 
residing in the colon, may cause C. difﬁ  cile-related antibiotic-
associated diarrhea and/or pseudomembranous colitis 
(Aronsson et al 1981, 1985; Ambrose et al 1985; Finegold 
1986; Edlund and Nord 2000). Finegold (1986) noted that, 
with the exception of vancomycin and parenterally adminis-
tered aminoglycosides, most other antimicrobial agents have 
been implicated in C. difﬁ  cile infections.
Systemic infections in immunocompromised patients, 
caused by normally innocuous microorganisms, have also 
been observed following antibiotic treatment. Superinfection, 
in which all major types of anaerobes have been involved, 
also has been associated with the use of antimicrobial 
agents. In general, antimicrobial-related complications are 
the result of suppression of the indigenous ﬂ  ora that prevent 
colonization and overgrowth by potential pathogens residing 
in the colon, which may cause diarrhea, colitis or other septic 
conditions (Finegold 1986).
Evaluation of the effect
of antimicrobial agents
on intestinal microﬂ  ora
The apparent consequences of exposure of the colonic micro-
ﬂ  ora to antimicrobial agents have been measured by enumera-
tion of bacterial species following clinical treatment of the 
patient or experimental exposure of volunteers to different 
antimicrobial agents (Nord and Edlund 1990). Evaluation of 
resistance patterns of anaerobic bacteria in saliva and feces 
of outpatients and hospitalized patients, regardless of treat-
ment with antibiotics, has shown an association among the 
relative numbers of antibiotic-resistant anaerobic bacteria, 
hospitalization, and antibiotic treatment. The number of 
resistant strains is correlated with the duration of antibiotic 
treatment (Stark et al 1993).
In numerous studies, scientists have evaluated the effects 
of antimicrobial agents on colonic bacteria by administering 
the antibiotics to their subjects and measuring their effects 
on the populations of various bacterial genera. All major 
classes of antimicrobial agents have been studied. Most of 
this work has been performed by Carl Nord’s laboratory at 
Karolinska University Hospital in Stockholm, Sweden, and 
several reviews have been written (Nord et al 1984a, 1984b, 
1988; Nord and Edlund 1990; Nord 1993; Edlund and Nord 
1999b; Sullivan et al 2001a). Fecal specimens, which have 
generally been accepted as representative of the colonic 
microbiota, were cultured on non-selective and selective 
media. Different colony types were counted, isolated in 
pure culture, and identiﬁ  ed to genus level. Their numbers 
were compared with the numbers of bacteria present from 
each genus before treatment to measure the effect of the 
antibiotic in decreasing the number of bacteria or allowing 
the increase, overgrowth or proliferation of others. All new 
colonizing bacteria were tested for susceptibility to the 
antibiotics that had been administered (Nord et al 2006a, 
2006b). The bacteria that were eliminated and those that 
overgrew other species were reported. The development of 
resistance among bacteria in the normal ﬂ  ora and overgrowth 
of microorganisms like yeasts, which are controlled by the 
normal microﬂ  ora, were also detected. In most cases, the 
populations of certain bacterial genera decreased while 
the number of bacteria from other genera increased. This 
increase was accompanied either by an increase in resistant Therapeutics and Clinical Risk Management 2008:4(6) 1346
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strains of bacteria or by overgrowth of fungi (Louie et al 
1985; Nilsson-Ehle et al 1985).
Rapid methods using DNA analysis also have been used 
to show the effects of antimicrobial agents on the human 
intestinal microflora. De La Cochetiere and colleagues 
(2005) isolated fecal DNA from volunteers after antibiotic 
treatment and ampliﬁ  ed bacterial 16S rRNA genes by PCR 
with general primers, which were analyzed by temporal 
temperature-gradient gel electrophoresis. By comparing the 
patterns of dominant species with the patterns generated 
before treatment, they determined the effects of treatments 
on alteration of the microbiota.
As the widespread emergence of various antimicrobial-
resistant bacteria has been problematic, and fatalities have 
resulted from the overgrowth of otherwise innocuous 
commensal microorganisms that do not respond to available 
antimicrobial agents, it appears timely to review the effects of 
these compounds on colonic microorganisms, with an empha-
sis on those that have not been covered in previous reviews.
β-Lactams
β-Lactams are the oldest and the most widely prescribed class 
of antibiotics; the class includes penicillins, cephalosporins, 
monobactams, carbapenems, and β-lactamase inhibitors.
Penicillins
The members of this group include phenoxymethylpenicillin, 
ampicillin, amoxicillin, piperacillin, azlocillin, temocillin, 
ticarcillin, pivampicillin, talampicillin, and bacampicillin.
Cephalosporins
Most of these are semisynthetic compounds and are not 
susceptible to cleavage of the β-lactam ring by many 
β-lactamases. They include cefaloridine, cefazolin, cefaclor, 
cephrocile, cefbuperazone, cefuroxime, cefoxitin, cefotiam, 
cefotaxime, cefoperazone, ceftriaxone, ceftazidime, ceftiazox-
ime, cefmenoxime, cefotetan, cephradine, and ceftibutan.
Monobactams
The β-lactam ring in monobactams is alone and not fused to 
another ring. Aztreonam is an example; it usually is used in 
combination with other drugs.
Carbapenems
As more and more bacteria develop resistance to β-lactam 
antimicrobial agents by producing various β-lactamases, 
efforts have been made to ﬁ  nd drugs that are not affected 
by β-lactamases. The carbapenems includes imipenem, 
meropenem, ertapenem, faropenem, doripenem, panipenem, 
and betamipron. Imipenem is inactivated in the kidney by 
a dehydropeptidase; to prevent this, it is used in combina-
tion with cilastatin, an inhibitor of kidney dehydropeptidase 
(Birnbaum et al 1985; Nord et al 1985). In addition to being 
resistant to β-lactamases, the carbapenems have broad anti-
bacterial activity.
β-Lactamase inhibitors
These compounds contain a β-lactam ring but have negligible 
antimicrobial activity. Because they bind to β-lactamases 
and prevent their attack on other β-lactams, they are 
co-administered with antimicrobial β-lactams.
Impact of treatment with β-lactams 
on the human intestinal microﬂ  ora
The impacts of different β-lactam antibiotics have been 
evaluated both in human volunteers and in patients undergo-
ing treatment. Various studies have considered the effects 
of the penicillin group: ampicillin (Leigh 1979), ampicil-
lin plus sulbactam (Kager et al 1982), piperacillin (Kager 
et al 1983), azlocillin (Nord et al 1986a), temocillin (van 
der Waaij 1985), and ticarcillin and clavulanic acid (Nord 
et al 1989) (Table 1). All of them decreased the numbers of 
enterobacteria, enterococci, and anaerobic bacteria. Treat-
ment with amoxicillin (Leigh and Nash 1979; Gipponi 
et al 1985) resulted in suppression of the numbers of 
enterobacteria in some trials but increased their numbers in 
others (Brismar et al 1993b). In some trials, overgrowth of 
C. difﬁ  cile was observed after treatment with amoxicillin, 
with or without clavulanic acid (Brismar et al 1993b; Lode 
et al 2001). Overgrowth by bacteria or Candida after the 
administration of the above drugs was observed in some 
trials. Ticarcillin/clavulanic acid administration resulted in 
increases in enterococci. Phenoxymethylpenicillin did not 
have much effect (Adamsson et al 1997).
Since β-lactams were the ﬁ  rst antibiotics to be discovered, 
they have been frequently prescribed for treatment of various 
infections and many bacteria have developed resistance to 
them. The presence of β-lactamases in various bacteria has 
resulted in the frequent ineffectiveness of these drugs. To avoid 
development of resistance and to enhance potency of the drugs, 
other β-lactams have been developed and used in combinations 
with β-lactamase inhibitors or other drugs (Table 2).
Pivmecillinam
Sullivan and colleagues (2001b) studied the impact of 
treatment with pivmecillinam on the intestinal microﬂ  oras Therapeutics and Clinical Risk Management 2008:4(6) 1347
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Table 1 Effects of penicillins, alone or in combination with other drugs, on intestinal microﬂ  ora
Compound Bacteria suppressed Bacteria proliferated Overgrowth Reference
Ampicillin Enterobacteria, enterococci, 
and anaerobic bacteria
Candida in some Leigh (1979)
Ampicillin and sulbactam Enterobacteria, enterococci, 
and anaerobic bacteria
Candida or C. difﬁ  cile in some Kager and colleagues (1982)
Piperacillin Enterobacteria, enterococci, 
and anaerobic bacteria
Candida or C. difﬁ  cile in some Kager and colleagues (1983)
Amoxicillin Enterobacteria Resistant enterobacteria Candida or C. difﬁ  cile in some Gipponi and colleagues 
(1985)
Ticarcillin and clavulanic acid Enterococci Candida or C. difﬁ  cile in some Nord and colleagues (1989)
Phenoxymethylpenicillin Little effect Adamsson and colleagues 
(1997)
of 15 individuals. They were treated for 7 days with 400 mg 
of pivmecillinam twice daily and then again 14 and 21 days 
after the start of administration. There was a decrease in the 
numbers of E. coli but no changes occurred in the anaerobic 
microﬂ  ora.
Piperacillin/tazobactam
The effect of piperacillin on the colonic bacteria has been 
reviewed (Nord and Edlund 1990). The impact on colonic 
ecology of its use in combination with a β-lactamase 
inhibitor, tazobactam, has also been investigated (Nord 
et al 1992, 1993; Nord and Lahnborg 1994). The effect of 
a piperacillin/tazobactam combination (4/0.5 g) on patients 
with intraabdominal infections who were treated three times 
a day for 8 days was evaluated; there were decreases in the 
mean numbers of enterobacteria, enterococci, and anaer-
obes (biﬁ  dobacteria, eubacteria, lactobacilli, clostridia, and 
Gram-positive cocci). Anaerobic Gram-negative cocci and 
Bacteroides spp. were unaffected (Table 2). The number 
of bacteria returned to normal after treatment was stopped 
(Nord et al 1992, 1993).
Omeprazole and amoxicillin
A combination of omeprazole (20 mg, a proton pump inhibi-
tor for eradication of Helicobacter pylori) and amoxicillin 
(1000 mg) twice daily for 14 days resulted in changes in the 
microﬂ  ora of the intestinal tract, increases in the numbers 
of resistant enterobacteria, and an increase in β-lactamase 
production detected in fecal samples (Stark et al 1995; 
Adamsson et al 1999).
Omeprazole/amoxicillin/
metronidazole combinations
The effects of amoxicillin in combination with antimicrobial 
agents effective against anaerobes also have been studied. 
Metronidazole, which is used for the treatment of anaerobic 
and parasitic infections, is also used in the treatment of 
H. pylori in combination with other drugs. Treatment of 
patients with a combination of 20 mg omeprazole, 1 g 
amoxicillin, and 40 mg metronidazole for 7 days resulted in 
alteration of normal microﬂ  ora and pronounced suppression 
of the anaerobic microﬂ  ora. During treatments, some patients 
also were colonized by yeasts. The MIC values of those drugs 
for Enterococcus spp. and the Enterobacteriaceae increased 
(Adamsson et al 1999).
Amoxicillin/clavulanic acid
Administration of 1000 mg of amoxicillin/clavulanic acid 
for 7 days to 12 healthy individuals (the same persons who 
had been treated with 600 mg linezolid for 7 days, with a 
washout period of 4 weeks between treatments) resulted 
in increases in the numbers of enterococci and E. coli and 
signiﬁ  cant decreases in the numbers of anaerobes, including 
biﬁ  dobacteria, lactobacilli, and clostridia. C. difﬁ  cile was 
isolated from three volunteers (Lode et al 2001). The authors 
concluded that unlike linezolid, amoxicillin/ clavulanic acid 
does not eliminate Gram-positive bacteria.
Ten volunteers who received 500 mg amoxicillin three 
times a day for 7 days were colonized with amoxicillin-
resistant bacteria, mostly E. coli, Klebsiella, and Enterobacter 
(Brismar et al 1993b). β-Lactamase activity was detected in 
the microﬂ  oras of six of the subjects.
Imipenem
Kager and colleagues (1988) evaluated the effects of imipe-
nem, both when used for treatment and for prophylaxis, on 
the intestinal microﬂ  ora. Use of 0.5 or 1 g of imipenem four 
times daily for 4–11 days resulted in a decrease in numbers of 
enterobacteria, anaerobic cocci, and Bacteroides spp. during 
treatment. The microﬂ  ora was restored to normal afterward. Therapeutics and Clinical Risk Management 2008:4(6) 1348
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) Patients receiving 0.5 or 1 g of imipenem for surgical 
prophylaxis, every 6 hours for 48 hours, had suppressed 
levels of staphylococci, streptococci, enterococci, entero-
bacteria, anaerobic bacteria, cocci, biﬁ  dobacteria, eubacteria, 
lactobacilli, clostridia, fusobacteria, and Bacteroides spp. 
during treatment; the levels were normal afterward. Coloni-
zation by imipenem-resistant bacteria did not occur (Kager 
et al 1988, 1989).
Aztreonam with either tobramycin 
or cloxacillin
Louie and colleagues (1985) used different combinations 
of drugs to treat febrile neutropenic patients and compared 
the impacts on the microbial ecology. Combinations of 
aztreonam with either tobramycin (15 subjects) or cloxacillin 
(14 subjects) resulted in the eradication of enteric Gram-
negative bacilli. These combinations also caused reduction 
of the numbers of fecal anaerobes, accompanied by a reduced 
concentration of short-chain fatty acids in fecal supernatants 
(Louie et al 1985). Fungal proliferation occurred in 27% of 
subjects receiving aztreonam/tobramycin and 43% of subjects 
receiving aztreonam/cloxacillin. Moxalactam/tobramycin 
combination treatments of 15 patients had similar effects on 
reduction of anaerobes and fungal acquisition (81%) as the 
previous two combinations. All of the subjects were febrile 
neutropenic patients, so the authors concluded that maintain-
ing the anaerobic ﬂ  ora was essential for the prevention of 
fungal acquisition in febrile neutropenic patients.
Meropenem
Intravenous injection of 500 mg meropenem three times daily 
for 7 days in 10 patients resulted in decreases in the numbers 
of enterobacteria and streptococci and increases in the numbers 
of enterococci, clostridia, Bacteroides spp., and Gram-negative 
cocci. Other Gram-positive cocci and rods were not affected. 
Two weeks after termination of therapy, the intestinal micro-
ﬂ  ora had returned to normal (Bergan et al 1991).
Ertapenem and ceftriaxone
Administration of either ertapenem (1 g per day) or ceftri-
axone (2 g per day) to 10 healthy individuals for 7 days via 
injection resulted in a 4-log reduction in E. coli as well as a 
reduction of the anaerobic microﬂ  ora, including lactobacilli, 
biﬁ  dobacteria, clostridia, and Bacteroides spp. There was a 
4-log increase in the number of enterococci. Overgrowth of 
yeast was observed in both treatments, but in both cases the 
microﬂ  ora returned to normal within 21–35 days after treat-
ment had concluded (Pletz et al 2004).Therapeutics and Clinical Risk Management 2008:4(6) 1350
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Cephalosporins
Various cephalosporins have major effects on the colonic 
microflora (Nord and Edlund, 1990). Cefbuperazone 
(Kager et al 1986), cefoxitin (Kager et al 1982), cefotaxime 
(Lambert-Zechovsky et al 1985), cefoperazone (Alestig et al 
1983), ceftriaxone (Arvidsson et al 1982), cefaclor (Nord 
et al 1987), and cefotetan (Ambrose et al 1985) all decreased 
the numbers of anaerobic bacteria and enterobacteria. All 
of these drugs, except cefoperazone and ceftriaxone, also 
decreased the number of enterococci in most treatments. 
Cefotaxime decreased both enterobacteria and enterococci in 
one trial. Cephaloridine (Ambrose et al 1985) and cephradine 
(Brumﬁ  tt et al 1986) had little effect. However, resistant 
bacterial strains developed as the result of administration of 
all of these drugs except for cephradine, ceftazidime and cef-
buperazone. C. difﬁ  cile emerged in some trials with cefepime, 
ceftriaxone, and ceﬁ  xime. Anaerobic Gram-positive cocci 
increased after treatment with both ceftriaxone and ceﬁ  xime 
(Nilsson-Ehle et al 1985, Sullivan et al 2001a). The effects 
of other cephalosporins (cefprozil, cefpodoxime proxetil, 
ceftibuten, and cefadroxil) on the intestinal ﬂ  ora are shown 
in Table 3.
Cefprozil
Administration of cefprozil resulted in changes in the popula-
tions of certain genera. Lode and colleagues (1992) studied 
the effects of cefprozil in eight individuals. They adminis-
tered 500 mg of cefprozil twice daily for 8 days and found 
that it resulted in moderate decreases in enterobacteria and 
slight increases in enterococci, staphylococci, and Bacteroi-
des spp. The microbial populations were normal 4 days after 
treatment. The major microbiologically related consequence 
was soft stools. In some cases, C. difﬁ  cile overgrowth was 
observed after treatment with cefprozil (Lode et al 1992).
Cefpodoxime proxetil
Cefpodoxime proxetil has major effects on the colonic bac-
teria. Brismar and colleagues (1993b) evaluated the effects 
of this compound on volunteers receiving 200 mg twice a 
day for 7 days. The numbers of streptococci, enterobacteria, 
and clostridia decreased substantially in the fecal ﬂ  ora, and 
overgrowth of enterococci, yeasts and Clostridium difﬁ  cile 
was observed (Brismar et al 1993b).
Cefadroxil
Administration of cefadroxil to healthy individuals does 
not cause measurable disturbance to the colonic ecology. 
Adamsson and colleagues (1997) evaluated the effect of 500 
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mg cefadroxil taken for 10 days by 20 healthy volunteers. The 
effect on the intestinal microﬂ  ora was slight and the micro-
ﬂ  ora was normal two weeks after withdrawal of the drug.
Ceftibuten
Brismar and colleagues (1993a) administered ceftibuten to 
14 healthy individuals. Each received a daily dose of 400 mg 
ceftibuten orally, but only two individuals had detectable 
levels of ceftibuten in the feces. During the administration 
period, the number of enterococci increased and the numbers 
of E. coli and anaerobic cocci decreased. Eight volunteers 
had increased levels of β-lactamases and six were colonized 
by C. difﬁ  cile.
Fluoroquinolones
Fluoroquinolones are a class of synthetic antimicrobial agents 
whose effects on the ecology of colonic microﬂ  ora have been 
intensively evaluated (Edlund and Nord 1988b; Edlund and 
Nord 1999b; Sullivan et al 2001a). By administration of 
different ﬂ  uoroquinolones and enumeration of bacteria from 
different genera before and after exposure, it was shown that 
ﬂ  uoroquinolones have a selective effect on the normal colonic 
bacteria. The effects of ciproﬂ  oxacin (Brismar et al 1990), 
norﬂ  oxacin (Edlund et al 1987a, 1987b; Edlund and Nord 
1988a), oﬂ  oxacin (Pecquet et al 1987; Edlund et al 1988), 
peﬂ  oxacin (Vollaard et al 1992), lomeﬂ  oxacin (Edlund et al 
1990), levoﬂ  oxacin (Edlund et al 1997b), sparﬂ  oxacin (Ritz 
et al 1994), ruﬂ  oxacin (D’Antonio et al 1996), sitaﬂ  oxacin 
(Inagaki and Yamamoto et al 1995), gatiﬂ  oxacin (Edlund 
and Nord 1999a), trovaﬂ  oxacin (Edlund and Nord 1999b), 
and moxiﬂ  oxacin (Edlund and Nord 1999b; Edlund et al 
2000b) on the intestinal microﬂ  ora have been analyzed. All 
of the ﬂ  uoroquinolones tested decreased the populations 
of enterobacteria, and peﬂ  oxacin decreased the number of 
aerobic Gram-positive cocci. In general, none of the ﬂ  uo-
roquinolones affected the anaerobic bacterial population. 
Overgrowth of bacteria as the result of ﬂ  uoroquinolones was 
not observed, but overgrowth of Candida was occasionally 
observed. Although C. difﬁ  cile infection was not observed, 
the use of newer ﬂ  uoroquinolones has been associated with 
the emergence of C. difﬁ  cile antibiotic-associated diarrhea in 
some hospitals. In vitro, we have shown that some strains of 
C. perfringens readily become resistant to ﬂ  uoroquinolones, 
even those that are generally effective against anaerobes 
(Raﬁ  i et al 2005). Resistant strains also exhibit physiologi-
cal changes that are different from wild-type strains. Simi-
larly, we have shown in vitro that one out of ﬁ  ve strains of 
C. perfringens produced a higher amount of toxin in response 
to gatiﬂ  oxacin exposure (Raﬁ  i et al 2008). The effects of 
some of the most recently developed fluoroquinolones 
(garenoxacin, gemiﬂ  oxacin, and clinaﬂ  oxacin) on colonic 
ecology have also been evaluated (Table 4).
Garenoxacin
Nord and colleagues (2003) evaluated the effects of oral 
administration of garenoxacin on the fecal microﬂ  oras of 
16 individuals. Administration of 600 mg garenoxacin daily 
for 6 days decreased the number of enterococci, bacilli, 
corynebacteria, enterobacteria, biﬁ  dobacteria, lactobacilli, 
clostridia, and Bacteroides spp. in the intestinal microﬂ  ora, 
and it increased the numbers of eubacteria. The microﬂ  ora 
returned to normal 2 weeks after discontinuation of this 
broad-spectrum fluoroquinolone. The concentrations of 
garenoxacin in fecal samples were 14–31 mg/kg. Garenoxa-
cin-resistant Eubacterium lentum (MIC = 64 mg/ml) was 
isolated from the subjects; the populations had returned to 
normal 14 days after discontinuation (Nord et al 2003).
Gemiﬂ  oxacin
The selective effect of gemiﬂ  oxacin on the intestinal micro-
ﬂ  ora was similar to that of other ﬂ  uoroquinolones (Barker 
et al 2001). Administration of 320 mg gemiﬂ  oxacin orally for 
7 days to 10 healthy subjects resulted in the suppression of 
enterobacteria, enterococci and streptococci. Anaerobic cocci 
and lactobacilli also decreased. Overgrowth or selection of 
resistant bacteria was not detected; the bacterial populations 
had returned to normal 49 days after treatment had stopped 
(Barker et al 2001).
Clinaﬂ  oxacin
Oh and colleagues (2000) evaluated the effects of clina-
ﬂ  oxacin on intestinal ecology in 12 healthy individuals and 
found major ecological disturbances. Oral administration of 
200 mg clinaﬂ  oxacin for 7 days resulted in high drug levels 
in feces (mean value 176 mg/kg on day 7). It eradicated the 
aerobic bacteria in 11 of the subjects and suppressed the 
anaerobic microﬂ  ora. Clinaﬂ  oxacin-resistant Bacteroides sp. 
(MIC  4) also emerged; Oh and colleagues (2000) recom-
mended restricting use of this drug.
Macrolides
Macrolides have a macrocyclic 14 to 16-membered lactone 
ring attached to a deoxy sugar. They include clarithromycin, 
dirithromycin, erythromycin, and roxithromycin, which have 
bactericidal or bacteriostatic activities. Their effects on the 
intestinal microﬂ  ora are summarized in Table 5.Therapeutics and Clinical Risk Management 2008:4(6) 1352
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Dirithromycin
Eckernas and colleagues (1991) evaluated the impact of 
treatment with dirithromycin of 20 healthy individuals on 
the colonic microbial population. Administration of 500 mg 
dirithromycin daily for 7 days resulted in the detection of 
12 mg/kg of dirithromycin in feces.
The numbers of enterobacteria and anaerobes (Gram-
positive cocci, biﬁ  dobacteria, eubacteria, and Bacteroides 
spp.) decreased in the intestinal ﬂ  ora and the numbers of 
streptococci, staphylococci, and other anaerobes (clostridia 
and lactobacilli) increased. In addition, dirithromycin-
resistant enterobacteria colonized the intestine. Eckernas 
and colleagues (1991) concluded that dirithromycin had a 
signiﬁ  cant ecological impact on the colonic bacteria.
Clarithromycin
Edlund and colleagues (2000a, 2000b) evaluated the 
ecological impact of clarithromycin in 12 volunteers. Admin-
istration of clarithromycin (500 mg twice daily for 7 days) 
caused signiﬁ  cant reduction of E. coli, while the numbers 
of enterococci, enterobacters, citrobacters, klebsiellas, and 
pseudomonads increased markedly. No signiﬁ  cant changes 
in the numbers of staphylococci, streptococci, bacilli, or 
Candida were noticed. In the anaerobic microﬂ  ora, biﬁ  do-
bacteria, lactobacilli and clostridia were suppressed, while no 
changes in peptostreptococci, Veillonella, Bacteroides spp., 
or fusobacteria were found. The microﬂ  ora was normal in 
all volunteers after 35 days. Edlund and colleagues (2000a, 
2000b) also found the emergence of Bacteroides spp. isolates 
that were resistant to clarithromycin after administration of 
500 mg of clarithromycin for 10 days to 10 patients. These 
bacteria persisted for 2 weeks after the drug was discontin-
ued. In the same study, the authors also found α-hemolytic 
streptococci, intestinal enterococci, and enterobacteria with 
resistance to clarithromycin, but no overgrowth of yeast or 
C. difﬁ  cile.
A combination of 20 mg of omeprazole, 250 mg of clar-
ithromycin, and 400 mg of metronidazole resulted in altera-
tion of the normal microﬂ  ora, similar to the combination 
of omeprazole, amoxicillin, and metronidazole (Adamsson 
et al 1999). The suppression of anaerobic microflora 
was more pronounced than that with the amoxicillin 
group. Substantial increases in clarithromycin-resistant 
Bacteroides strains, from 2% to 76%, were observed during 
treatment. Both combinations altered the fecal microﬂ  ora, 
but the clarithromycin combination therapy had more 
undesirable effects on the colonic ecosystem (Adamsson 
et al 1999).Therapeutics and Clinical Risk Management 2008:4(6) 1353
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Erythromycin
Brismar and colleagues (1991) administered 1 g of eryth-
romycin ethyl succinate orally for 7 days to 10 volunteers 
and evaluated its effect on the colonic bacteria. They found 
decreases in the numbers of streptococci, enterococci, and 
enterobacteria during administration, increases in staphylo-
cocci, and alteration of the anaerobic bacteria. In an earlier 
study (Heimdahl and Nord 1982), it had been shown that the 
administration of 500 mg of erythromycin twice daily for 
7 days to 10 volunteers resulted in decreases in enterobacteria 
and most anaerobes. In addition, potentially pathogenic 
erythromycin-resistant enterobacteria, clostridia or yeasts 
colonized all subjects (Heimdahl and Nord 1982).
Ketolides
This is a new class of compounds related to the macrolides 
and includes telithromycin (Nord et al 2004), which differs 
from erythromycin in having a large aromatic side chain 
and substitution of sugar with a keto group. Ketolides can 
bind to two sites on the bacterial ribosome; therefore, they 
are effective even against macrolide-resistant bacteria. They 
also have reduced potential for inducing ketolide-resistant 
bacteria. Edlund and colleagues (2000a) studied the effect of 
telithromycin in ten subjects and found an increase in the MIC 
of telithromycin for resistant Bacteroides spp. isolates, which 
persisted for 2 weeks after the drug was discontinued. How-
ever, overgrowth of yeast and C. difﬁ  cile was not observed.
Aminoglycosides
Amikacin, gentamicin, kanamycin, neomycin, netilmicin, 
paromomycin, rhodostreptomycin, streptomycin, tobra-
mycin, and apramycin are examples of aminoglycosides. 
Finegold (1986) noted an association between administra-
tion of “intestinal antiseptics,” such as oral neomycin, and 
superinfection by anaerobes.
Glycylcyclines
Glycylcyclines, a new class of antibiotics, are tetracycline 
analogs developed with features to prevent either their efﬂ  ux 
from the cells or the development of ribosomal protection 
proteins, which result in resistance to tetracyclines.
Tigecycline
Tigecycline is a glycylcycline, which has a potent broad-
spectrum activity against most Gram-positive and Gram-
negative aerobic and anaerobic bacteria. Administration of 
50 mg tigecycline to 20 subjects every 12 hours for 10 days 
(Nord et al 2006b) resulted in a reduction in the numbers 
of enterococci, E. coli, lactobacilli, and bifidobacteria, 
and increases in other enterobacteria and yeasts. Two 
tigecycline-resistant strains of Klebsiella pneumoniae and 
ﬁ  ve tigecycline-resistant strains of Enterobacter cloacae 
developed (Nord et al 2006b).
Lincosamides
Lincomycin and clindamycin are lincosamides, which inhibit 
transpeptidase reactions by binding to the 23 S and 50 S 
subunits of bacterial ribosomes and inhibiting early elonga-
tion of peptide chains.
Clindamycin
Clindamycin is used for the treatment not only of anaero-
bic infections, but also of parasitic infections, including 
malaria. Administration of clindamycin to 10 subjects for 
7 days resulted in the disturbance of colonic ecology (Kager 
et al 1981). Clindamycin is also associated with C. difﬁ  cile 
antibiotic-associated diarrhea. Kager and colleagues (1981) 
evaluated the effect of 600 mg of intravenous clindamycin at 
8-hour intervals for 48 hours, which resulted in the decrease 
of enterococci, streptococci, and anaerobic bacteria. After 
treatment, streptococci and anaerobic bacteria proliferated; 
postoperative infection due to Enterococcus faecalis occurred 
in some of the patients.
Oxazolidones
Linezolid belongs to the class of antimicrobial agents called 
oxazolidones. It is a synthetic antibiotic, rarely used because 
of its high price, but it is effective for the treatment of mul-
tidrug-resistant bacterial infections, including those caused 
by Streptococcus spp. and MRSA. Administration of 600 mg 
of linezolid for 7 days to healthy volunteers resulted in the 
suppression of enterococci and increases in the numbers of 
Klebsiella spp. It also decreased the numbers of the following 
anaerobes: biﬁ  dobacteria, lactobacilli, clostridia, and Bacte-
roides spp. Thirty-ﬁ  ve days after termination of treatment, 
the microﬂ  ora was normal (Lode et al 2001).
Glycopeptides
This class consists of glycosylated cyclic nonribosomal 
peptides and includes vancomycin, teicoplanin, telavancin, 
tramplanin, decaplanin, and dalbavancin, which is a lipogly-
copeptide. They inhibit peptidoglycan synthesis.
Vancomycin
This drug has been used as the last resort for treatment of 
infections caused by Gram-positive bacteria. Edlund and Therapeutics and Clinical Risk Management 2008:4(6) 1355
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colleagues (1997a) evaluated the effects of vancomycin in 
10 individuals after treatment with 250 mg of cefuroxime 
axetil twice daily for 7 days. The subjects then received 
125 mg of vancomycin four times daily for 7 days. The 
authors concluded that vancomycin causes ecological 
disturbances of the intestinal microﬂ  ora. Vancomycin treat-
ment resulted in decreases in the numbers of Enterococcus 
faecium, E. faecalis, and E. durans and of anaerobes, includ-
ing biﬁ  dobacteria and Bacteroides spp. It also resulted in the 
emergence of motile enterococci, including E. gallinarum and 
E. casseliﬂ  avus strains with decreased susceptibility to van-
comycin (MIC = 4–16 mg/ml). Some of these strains had the 
vanC2 (C3) gene. In addition, vancomycin-resistant strains 
of Pediococcus, Lactobacillus, Klebsiella, Citrobacter, and 
Enterobacter species also emerged. Recently, other inves-
tigators have shown that oral vancomycin promotes the 
overgrowth of vancomycin-resistant enterococci (Al-Nassir 
et al 2008).
Dalbavancin
This is a novel lipoglycopeptide, related to vancomycin, and 
similarly to that drug it is used for treatment of MRSA and 
S. epidermidis. Nord and colleagues (2006a) evaluated the 
effect of this drug in 12 individuals. When 1 g dalbavancin 
was given to six men and six women, there were some 
changes in numbers of enterococci and E. coli but no changes 
in numbers of lactobacilli, clostridia, and Bacteroides spp. 
No C. difﬁ  cile strains were recovered. No newly colonizing 
aerobic or anaerobic bacteria with resistance to dalbavancin 
were found. Dalbavancin apparently has no major ecological 
effects on the normal human intestinal microﬂ  ora (Barker 
et al 2001, Nord et al 2006a).
Metronidazole
Metronidazole is used for the treatment of anaerobic bacte-
rial infections and is also used in combination with other 
drugs for treatment of ulcerative colitis. It has been shown to 
eliminate methanogenic Archaea (Ansorg et al 2003). Use of 
oral metronidazole for the treatment of C. difﬁ  cile-associated 
disease has resulted in the overgrowth of enterococci, includ-
ing vancomycin-resistant strains (Al-Nassir et al 2008).
Conclusions
The colonic microﬂ  ora provides a number of beneﬁ  ts, includ-
ing contributing to the host’s nutrition and protecting the host 
from infection. In most cases of antimicrobial therapy, the 
bacterial populations in some genera are reduced in numbers 
while those in other genera increase. In some cases, the 
increased numbers of certain bacteria are accompanied by 
resistant strains of bacteria or overgrowth by fungi. Treat-
ment with antimicrobial combinations does not necessarily 
prevent resistance development. It may even result in fungal 
overgrowth and appearance of bacteria with resistance to all 
of the drugs in the combination. Examples are the amoxicillin 
and metronidazole combination and the aztreonam combi-
nation with either tobramycin or cloxacillin, all of which 
result not only in the suppression of anaerobes but also in 
the overgrowth of fungi. Some of the anaerobic bacteria may 
keep the fungi in check. A review of the impact of antimicro-
bial agents on colonic ecology also shows variation among 
individuals in response to treatment with these drugs and 
variation in the effects of these drugs on different strains of 
the same bacterium. Toxin-producing strains of C. difﬁ  cile 
have been found in some hospitals after ﬂ  uoroquinolone 
therapy, and some strains of C. perfringens produce toxin 
after gatiﬂ  oxacin exposure. The importance of judicious use 
of these important drugs cannot be overemphasized.
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